報價延遲最少15分鐘:2024/05/18 15:54 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
139.82 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
8.82/10.76
|
|
企業價值
22.57B
|
| 資產負債 |
|
每股賬面淨值
10.56
|
| 現金流量 |
|
現金流量率
0.12
|
| 損益表 |
|
收益
12.14B
|
|
每股收益
135.81
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/18 15:54 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treatsover 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business. |